作者
Wibool Ridtitid, Malinee Wongnawa, Werawath Mahatthanatrakul, Jarurat Punyo, Methi Sunbhanich
发表日期
2002/11
期刊
Clinical Pharmacology & Therapeutics
卷号
72
期号
5
页码范围
505-513
简介
Background and Objective
Praziquantel is extensively metabolized by the hepatic cytochrome P450 (CYP) enzymes. The CYP3A isoforms are likely to be major enzymes responsible for praziquantel metabolism. Rifampin (INN, rifampicin), a potent enzyme inducer of CYP‐mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs. The aim of this investigation was to study the possible pharmacokinetic interaction between rifampin and praziquantel.
Methods
An open, randomized, 2‐phase crossover design was used in each study of single or multiple doses. In the single‐dose study, 10 healthy Thai male volunteers ingested single doses of 40 mg/kg praziquantel alone (phase 1) or after pretreatment with 600 mg of oral rifampin once daily for 5 days (phase 2). In the multiple‐dose study, all participants …
引用总数
200620072008200920102011201220132014201520162017201820192020202120222023543324126415314531
学术搜索中的文章
W Ridtitid, M Wongnawa, W Mahatthanatrakul, J Punyo… - Clinical Pharmacology & Therapeutics, 2002